Scientists have found an unexpected effect of the interaction of these two genes in early stage prostate cancer. Researchers found that prostate tumor growth is arrested through a biological process called cellular senescence, in which cells stop proliferating and remain alive but fail to respond to normal growth signals.
In a potential advance for the treatment of aggressive breast cancer, scientists have identified a set of genes in breast tumors that appear to predict if the disease will spread to the lungs and, once there, how virulent it will become.
Memorial Sloan-Kettering Cancer Center announces the establishment of a new graduate school of biomedical sciences. It will offer a novel doctoral program that will train basic laboratory scientists to work in research areas directly applicable to human disease and, in particular, to cancer.
According to research published today, investigators have used new techniques in the laboratory that allowed them for the first time to derive unlimited numbers of purified mesenchymal precursor cells from human embryonic stem cells.
Scientists have uncovered the structure of a network of proteins that help regulate the life cycle of cells. Understanding the network's physical layout is an important step toward learning its precise function, and in finding ways to correct flaws in the system that could lead to cancer.
Three New York City biomedical research institutions -- The Rockefeller University, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center -- will receive $50 million over three years from The Starr Foundation to develop new resources and expertise in stem cell research.
Three New York City biomedical research institutions will receive $50 million over three years from The Starr Foundation to develop new resources and expertise in stem cell research.
A prospective, randomized trial comparing a novel regimen with a standard treatment for adult patients with acute lymphocytic leukemia showed a distinct advantage that continued to show superior results at three-, four-, and five-year intervals in the investigational arm of the trial.
Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer.
Scientists at Memorial Sloan-Kettering Cancer Center have identified a new cellular oncogene essential for the development of cancer. Oncogenes are genes that, when mutated or dysfunctional, lead normal cells to become cancerous.
A new study by researchers at Memorial Sloan-Kettering Cancer Center and The Johns Hopkins University provides new insight into how tumor cells can become resistant to anti-cancer therapy.
Memorial Sloan-Kettering Cancer Center today announced the establishment of a new graduate school of biomedical sciences. It will offer a novel doctoral program that will train basic laboratory scientists to work in research areas directly applicable to human disease and, in particular, to cancer.
A study describes a previously unsuspected capacity of embryonic stem cells to influence neighboring defective cells and restore their capacity to function normally.
Mesothelioma is an aggressive cancer of the chest cavity that kills about 2000 people a year in the United States. It has also been proposed that simian virus 40 (SV40), a contaminant in some polio vaccines administered in the 1950's and 1960's, might be a cause.
Many cancers, including colon, prostate, and leukemia, continue to grow unchecked because they do not respond to a signal to die and stop proliferating from Transforming Growth Factor-beta (TGF-b).
If you are a black Medicare patient in the United States, you are more likely than a white Medicare patient to be treated by a primary care physician who reports being unable to provide consistently high-quality medical care to all patients.
James Allison, PhD, has been named the new Chairman of the Immunology Program at Memorial Sloan-Kettering Cancer Center (MSKCC). He succeeds Alan Houghton, MD, who has led the Program since 1995.
A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers.
A study shows that the risk for prostate cancer is significantly elevated in men from families with a hereditary form of breast and ovarian cancer. Researchers have found that men in families with BRCA genetic mutations have a 3 to 5-fold increased risk of prostate cancer.
An estimated 68,500 women will die from lung cancer this year. The increase in the number of women smokers is an obvious cause, but a recent review article suggests that genetic, metabolic, and hormonal factors may also be responsible. Lung cancer in women has reached epidemic proportions in the US.
A new anti-cancer agent, gefinitib (Iressa), recently received FDA approval for patients with advanced non-small cell lung cancer. The compound is designed to target and block the activity of the tyrosine kinase enzyme that signals the epidermal growth factor receptor.
MSKCC is pleased to announce the appointment of David Spriggs, MD, as Head of the Division of Solid Tumor Oncology in the Department of Medicine.
An abnormal or rising PSA blood test is often the first indication that a man may have prostate cancer. However, after a man has received curative therapy, there is uncertainty about what the PSA measurement means since the relationship of tumor mass and PSA value is less established at this time.
Researchers have developed a new computerized tool called a nomogram that will help patients and their physicians calculate the likelihood of breast cancer spreading beyond the sentinel lymph nodes to additional lymph nodes under the arms (axilla).
Memorial Sloan-Kettering Cancer Center is pleased to announce the appointment of Larry Norton, MD as Deputy Physician-in-Chief for Breast Cancer Programs. Dr. Norton formerly served as the Chief of the Division of Solid Tumor Oncology in the Department of Medicine.
One or both copies of the PTEN tumor suppressor gene are found to have been lost in 70 percent of prostate cancer patients at the time of diagnosis. It has generally been believed that one remaining copy would still protect against tumor progression to advanced metastatic cancer.
Memorial Sloan-Kettering Cancer Center has announced the recipients of the Paul Marks Prize for Cancer Research, a $125,000 award to be shared by three young investigators who already have made major accomplishments in cancer research.
Memorial Sloan-Kettering Cancer Center has launched its first major capital campaign since the 1980s. With a goal of raising $1 billion over five years, the Campaign for Memorial Sloan-Kettering will provide the means to expand the Center's programs and facilities in fast-emerging areas.
David Kissane, M.D. has been named Chairman of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan-Kettering Cancer Center (MSKCC).
A new anti-cancer agent designed to block the signals responsible for telling cancer cells to grow has shown promising results for patients with advanced non-small cell lung cancer. A subset of the data from this clinical trial formed the basis for approval of the drug by the FDA.
New research shows that men with clinically localized prostate cancer, treated to high dose levels with three-dimensional conformal radiation therapy (3D-CRT), achieved long-term PSA relapse-free survival (PRFS) with minimal side effects.
New research shows that pediatric brain tumors and Fanconi anemia can develop among children in the rare instance that both parents carry mutations of the BRCA2 gene.
Mary McCabe, RN, MA has joined Memorial Sloan-Kettering Cancer Center as Director of a new Cancer Survivorship Program, a Center-wide initiative intended to address the long-term medical, psychological, and social consequences of cancer and its treatment.
Scientists found that by inhibiting both the proteins responsible for breast cancer growth and those required for the formation of new blood vessels, they could more effectively suppress the growth of extremely aggressive breast tumors in mice.
New research describes a novel way of producing therapeutic nerve cells that can cure mice with Parkinson's-like disease. The work provides the first evidence that cloned cells can cure disease in an animal model.
1) An Ounce of Prevention: Cancer Screening; 2) Investigators Use X-rays, Crystals to Understand the Mechanisms of Cancer; 3) New Imaging Method Allows Tracking of T Cells to Tumors In Mice
New research presented today finds that Magnetic Resonance Imaging is a highly sensitive screening tool that may detect breast cancers missed by mammograms in women who are at increased risk for developing the disease.
A new study suggests that a drug called erlotinib has promising activity in patients with bronchioloalveolar cell carcinoma, a type of non- small cell lung cancer generally considered to be resistant to chemotherapy. Researchers from Memorial Sloan-Kettering Cancer Center reported the preliminary results today.
A PSA blood test is part of routine prostate cancer screening for most men over 50. If the test result shows a moderately elevated PSA level, a referral for a biopsy is usually recommended. There is now evidence that suggests biopsy should not be performed until the test is repeated because PSA levels commonly fluctuate above and below the normal range.
For more than 40 years, it has been accepted that radiation kills tumors by damaging their DNA and that other elements that are part of the tumor mass, such as connective tissue and blood vessels, are minimally affected by radiation or not at all. New research challenges this notion.
Through an innovative partnership, The Ralph Lauren Center for Cancer Care and Prevention has opened its doors to provide individuals -- many of whom are medically underserved -- with access to the highest quality cancer screening and treatment services.
For nine dogs that naturally developed canine malignant melanoma, treatment with a new DNA-based vaccine more than tripled their median survival from an expected 90 days to an average of 389 days.
Smoking, the number one cause of preventable death in the United States, causes 130,000 lung cancer deaths each year. Many smokers are now considering screening with low-dose helical computed tomography scans in the hope of diagnosing the disease early.
Nominations are currently being sought for the Paul Marks Prizes for Cancer Research. These awards, established by Memorial Sloan-Kettering Cancer Center two years ago, are named for Paul A. Marks, MD, President Emeritus of the Center and a distinguished scientist.
Researchers have developed a novel approach to genetically instruct human immune cells to recognize and kill cancer cells in a mouse model. The investigators plan to ultimately apply this strategy in a clinical trial setting for patients with certain forms of leukemias and lymphomas.
Marc Rosenblum, MD, has been named Chairman of the Department of Pathology at Memorial Sloan-Kettering Cancer Center.
A rare genetic syndrome, Dyskeratosis Congenita (DC), may hold the key to understanding a mechanism that causes premature aging and cancer.
A unique web-based resource about herbs, botanicals, and other products has been launched to provide medical practitioners, as well as the general public, access to comprehensive information about these products.
Research sheds light on why certain cancer cells die (apoptosis) in response to chemotherapy, while others stop proliferating (citostasis) and try to repair the damaging effects of the drug. For years, scientists have tried to understand what determines this choice - citostasis versus apoptosis - in order to influence that decision in favor of cell death during the course of treatment.
James E. Rothman, PhD, a cell biologist whose career has focused on elucidating the underlying mechanisms of transport within cells, is a winner of the 2002 Albert Lasker Award for Basic Research.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right